Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Tuscano

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphomaPeter H Wiernik, Izidore S Lossos, Joseph M Tuscano, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2021
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I TrialSwetha Kambhampati, Bita Fakhri, Weiyun Z Ai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
Leukemia Research|June 23, 2022
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer centerTamer Othman, Benjamin N Moskoff, Gwendolyn Ho, et al.
British Journal of Haematology|March 4, 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 studyMichael Wang, Leslie L Popplewell, Robert H Collins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialRanjana H Advani, Fangxin Hong, Richard I Fisher, et al.
British Journal of Haematology|September 8, 2015
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraCatherine S Diefenbach, Hailun Li, Fangxin Hong, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
British Journal of Clinical Pharmacology|July 5, 2019
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunctionNaoko Takebe, Jan H Beumer, Shivaani Kummar, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphomaPeter H Wiernik, Izidore S Lossos, Joseph M Tuscano, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2021
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I TrialSwetha Kambhampati, Bita Fakhri, Weiyun Z Ai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
Leukemia Research|June 23, 2022
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer centerTamer Othman, Benjamin N Moskoff, Gwendolyn Ho, et al.
British Journal of Haematology|March 4, 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 studyMichael Wang, Leslie L Popplewell, Robert H Collins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialRanjana H Advani, Fangxin Hong, Richard I Fisher, et al.
British Journal of Haematology|September 8, 2015
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraCatherine S Diefenbach, Hailun Li, Fangxin Hong, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
British Journal of Clinical Pharmacology|July 5, 2019
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunctionNaoko Takebe, Jan H Beumer, Shivaani Kummar, et al.
Pageof 7